Moratorium pushes Glenmark to new Indian site for Napo's crofelemer
This article was originally published in Scrip
A Indian government-imposed temporary moratorium on new projects in Ankleshwar is said to have forced Glenmark to consider an alternative site in Aurangabad for manufacturing the active pharmaceutical ingredient (API) for Napo Pharmaceuticals' anti-secretory gastrointestinal agent, crofelemer. However, the company says that the moratorium is a general one and nothing to do with any of Glenmark's specific processes or plants.
You may also be interested in...
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.